Mirum Pharmaceuticals, Inc. (MIRM)
| Market Cap | 6.37B +69.8% |
| Revenue (ttm) | 618.07M +44.0% |
| Net Income | -860.21M |
| EPS | -15.34 |
| Shares Out | 64.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 419,830 |
| Open | 97.46 |
| Previous Close | 97.46 |
| Day's Range | 95.61 - 98.40 |
| 52-Week Range | 63.23 - 130.00 |
| Beta | 0.51 |
| Analysts | Strong Buy |
| Price Target | 138.21 (+40.96%) |
| Earnings Date | Aug 5, 2026 |
About MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is ap... [Read more]
Financial Performance
In 2025, Mirum Pharmaceuticals's revenue was $521.31 million, an increase of 54.74% compared to the previous year's $336.89 million. Losses were -$23.36 million, -73.43% less than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for MIRM stock is "Strong Buy." The 12-month stock price target is $138.21, which is an increase of 40.96% from the latest price.
News
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum sinks after FDA recommends conducing Phase 3 study
Shares of Mirum Pharmaceuticals (MIRM) are moving lower after disclosing the FDA asked for a late-stage study in sclerosing cholangitis. At a recent pre-new drug application meeting, the agency recomm...
Mirum Pharmaceuticals price target lowered to $123 from $129 at Baird
Baird lowered the firm’s price target on Mirum Pharmaceuticals (MIRM) to $123 from $129 and keeps an Outperform rating on the shares.
Mirum Pharmaceuticals price target lowered to $140 from $145 at TD Cowen
TD Cowen lowered the firm’s price target on Mirum Pharmaceuticals (MIRM) to $140 from $145 and keeps a Buy rating on the shares. The firm said Management again raised guidance…
Mirum Pharmaceuticals price target lowered to $137 from $150 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Mirum Pharmaceuticals (MIRM) to $137 from $150 and keeps an Overweight rating on the shares. The base business delivered “again” and the…
Mirum Pharmaceuticals price target lowered to $135 from $148 at RBC Capital
RBC Capital lowered the firm’s price target on Mirum Pharmaceuticals (MIRM) to $135 from $148 and keeps an Outperform rating on the shares. Mirum delivered a strong Q2 beat-and-raise with…
Mirum Pharmaceuticals price target lowered to $140 from $185 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on Mirum Pharmaceuticals (MIRM) to $140 from $185 and keeps a Buy rating on the shares. The firm says the…
Mirum Pharmaceuticals price target lowered to $137 from $146 at Citizens
Citizens analyst Jonathan Wolleben lowered the firm’s price target on Mirum Pharmaceuticals (MIRM) to $137 from $146 and keeps an Outperform rating on the shares. Mirum delivered a strong commercial…
Mirum Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 2026 net product sales rose to $176 million, prompting an increase in full-year guidance to $680M-$700M. Pipeline progress includes a potential FOP launch and delayed NDA for volixibat in PSC due to ongoing FDA discussions. Cash position and margins improved.
Mirum Pharmaceuticals Earnings release: Q2 2026
Mirum Pharmaceuticals released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Mirum Pharmaceuticals Quarterly report: Q2 2026
Mirum Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 5, 2026.
Mirum Pharmaceuticals reports Q2 EPS ($1.06), consensus (75c)
Reports Q2 revenue $176.2M, consensus $166.37M. “Mirum delivered another strong quarter, with continued commercial momentum supporting an increase to our full-year net product sales guidance and launc...
Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update.
Mirum Pharmaceuticals Slides: Corporate presentation
Mirum Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026.
Mirum treatment of primary sclerosing cholangitis granted FDA orphan status
Mirum Pharmaceuticals (MIRM)’ volixibat was granted FDA orphan designation as a treatment of primary sclerosing cholangitis, according to a post to the agency’s website.
Arcutis appoints Mirum Pharmaceuticals CEO Christopher Peetz to board
Arcutis Biotherapeutics (ARQT) announced that Christopher Peetz has been appointed to the Arcutis board of directors effective July 15. Peetz currently serves as a co-founder and chief executive offic...
Mirum Pharmaceuticals price target raised to $148 from $142 at RBC Capital
RBC Capital analyst Lisa Walter raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $148 from $142 and keeps an Outperform rating on the shares as part of a…
Mirum Pharmaceuticals price target raised to $125 from $115 at JPMorgan
JPMorgan raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $125 from $115 and keeps an Overweight rating on the shares.
Mirum Pharmaceuticals Slides: Corporate presentation
Mirum Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
Mirum Pharmaceuticals price target raised to $146 from $140 at Citizens
Citizens analyst Jonathan Wolleben raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $146 from $140 and keeps an Outperform rating on the shares. Mirum’s acquisition of zilurgisertib i...
Incyte, Mirum announces Phase 2 results from Cohort 1 of Progress study
Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced Phase 2 results from Cohort 1 of the Progress study evaluating zilurgisertib, an investigational oral activin receptor-like kinase 2 inhibitor,...
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in FOP.
Mirum Pharmaceuticals Slides: Study update presentation
Mirum Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 13, 2026.
Mirum Pharmaceuticals price target raised to $150 from $140 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $150 from $140 and keeps an Overweight rating on the shares. Hepatitis delta virus remains underdiagnosed and recent…